Rani Therapeutics to Participate in September Investor Conferences

SAN JOSE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that Rani will participate in and present at two upcoming investor conferences in September 2023. These conferences include:

H.C. Wainwright 25^th Annual Global Investment Conference
Date: Monday, September 11^th at 10:30 am E.T.
Format: Formal Presentation and 1x1 Investor Meetings
Presenter: Chief Executive Officer, Talat Imran

Cantor Fitzgerald Global Healthcare Conference
Date: Thursday, September 28^th at 8:35 am E.T.
Format: Formal Presentation and 1x1 Investor Meetings
Presenter: Chief Executive Officer, Talat Imran

Interested parties can register for and access the live webcasts for these conferences by visiting the “Events” section of the Rani Therapeutics website. The webcast replays will be available after the conclusion of the respective presentations.

About Rani Therapeutics

Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani is progressing two RaniPill capsules, the RaniPillGO and the RaniPillHC. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill capsule technology. For more information, visit ranitherapeutics.com.

Investor Contact:
[e-mail]

Media Contact:
[e-mail]